FOI 2026 1808

Under the Freedom of Information Act 2000, in your role commissioning specialised immunology services (delegated from April 2025), please provide aggregate counts only (standard suppression accepted):

1. The number of Blueteq / high-cost-drug prior approvals in force for hereditary angioedema long-term prophylaxis, by medicine (lanadelumab, berotralstat, garadacimab, plasma-derived C1-INH), for each month/quarter from January 2023 to the latest available.
2. Where recorded, these counts by patient ICB of residence / responsible commissioner.
3. The provider(s) through which these patients are managed (e.g. which specialist centre), so cross-boundary flow can be understood.

No patient-identifiable data and no pricing/PAS information is requested. Please supply CSV/Excel. If over the cost limit, advise and I will narrow (e.g. a single recent quarter).

Questions 1 – 3.  NHS Greater Manchester (NHS GM) does not hold the information requested. The medicines referenced in the request are under responsibility of NHS England (NHSE).  Therefore, it will be necessary for you to contact them directly for the information you seek. To assist you please find below a link to their website and information about how to make a Freedom of Information request.

NHS England » Freedom of Information Act and Environmental Information Regulations